Ruxolitinib

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Ruxolitinib and local guidelines before prescribing.

JAK inhibitor

Mechanism

JAK1 and JAK2 inhibitor.

Uses

Myelofibrosis, polycythaemia vera, graft-versus-host disease.

Dosing

Side effects

Anaemia, thrombocytopenia, infections, bruising, weight gain.

Interactions

CYP3A4 inhibitors raise levels.

Contraindications and cautions

Active serious infection

Monitoring

FBC, LFT

Pregnancy and breastfeeding

Avoid

Renal and hepatic impairment

Dose by platelets and renal function

Overdose and reversal

Supportive

Special advice

Do not stop abruptly; FBC monitoring.

More from the textbook: uses, cautions and other points
Where it is discussed in the book